Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-08-27 Share Issue/Capital Cha…
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Proposed c.£11m Fundraise
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Ondine Biomedical Inc. regarding a proposed fundraising (placing and subscription) and a trading update. It details the capital raise amount, the purpose of the funds, the issuance of new common shares, and provides a summary of financial performance for H1 2025. Because the primary purpose of the document is to announce a capital raise and financing activity, it falls under the 'Capital/Financing Update' category.
2025-08-27 English
First Mexican Hospital Steriwave Deployment
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's RNS (Reach) service. It announces a specific operational update regarding a new hospital pilot program for the company's Steriwave product in Mexico. As it is a general corporate announcement that does not fit into specific categories like financial reports, dividends, or board changes, it falls under the RNS (Regulatory Filings) category.
2025-08-13 English
Ex-President of Mexico Champions APDT to Cut AMR
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS (Regulatory News Service) Reach platform. It announces a strategic partnership between Ondine Biomedical Inc. and the International Photodynamic Association to launch the 'Light Against AMR Initiative'. As this is a corporate announcement regarding a business initiative and does not fit into specific categories like financial reports, board changes, or dividend notices, it falls under the general regulatory/corporate announcement category.
2025-08-11 English
Share Issuance for ICU Study Enrollment Completion
Share Issue/Capital Change Classification · 99% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange, approved by the FCA. The content announces the issuance of new common shares following the completion of a milestone in a clinical trial. This action—issuing shares as part of a contractual obligation (milestone payment)—is a change in capital structure or a financing-related event. Since it involves the issuance of shares, it strongly aligns with the 'Share Issue/Capital Change' definition (SHA). While it could potentially be seen as a financing update (CAP), the specific action is the issuance of shares, making SHA more precise. It is not a general regulatory announcement (RNS) because it details a specific corporate action (share issuance) rather than just disseminating information.
2025-07-22 English
UK Axes Financial support for AMR Fleming Fund
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 8284R' and concludes with the statement 'This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This strongly indicates a general regulatory announcement distributed via the RNS system. The content is a press release discussing the cancellation of the UK's Fleming Fund and how Ondine Biomedical's technology addresses the resulting gap in antimicrobial resistance (AMR) solutions. It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific shareholder document (like DEF 14A or DVA). Since it is a general announcement distributed through the regulatory feed (RNS) that doesn't fit a more specific category (like DIV, CAP, or MANG), the most appropriate classification is the general regulatory announcement fallback category.
2025-07-21 English
Steriwave ICU Study Completes Recruitment
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8279R' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority (FCA) as a Primary Information Provider. The content itself is an announcement regarding the completion of recruitment for a clinical study ('Steriwave ICU Study Completes Recruitment') by Ondine Biomedical Inc. This is a specific operational/scientific update, not a comprehensive financial report (10-K, IR), a formal earnings release (ER), or a proxy statement (DEF 14A/PSI). Since it is a formal, time-sensitive announcement distributed via the official regulatory news service (RNS), and it doesn't fit neatly into the other specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory announcement category, RNS.
2025-07-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.